VRAX Virax Biolabs Group Ltd IFRS Annual reports only
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1885827 · Fiscal year ends 03/31
Financial factors as of 2025-03-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-03-31 | FY20242024-03-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6,331 | $156,419 |
| Cost of revenue | $59,398 | $105,829 |
| Gross profit | -$53,067 | $50,590 |
| R&D expense | $1.78M | $1.56M |
| SG&A expense | $4.33M | $4.59M |
| Operating income | -$6.16M | -$6.50M |
| Pretax income | -$6.20M | -$6.74M |
| Income tax | -$136,661 | — |
| Net income | -$6.06M | -$6.73M |
| EBITDA | -$5.90M | -$6.44M |
| EPS (basic) | -1.62 | -3.36 |
| EPS (diluted) | -1.62 | -3.36 |
| Weighted avg. shares (diluted) | 3.73M | 2.01M |
| Banking | ||
| Net interest income | $58,179 | -$26,878 |
| Balance sheet | ||
| Cash & equivalents | $4.23M | $3.59M |
| Inventory | $94,675 | $60,383 |
| Current assets | $4.89M | $4.38M |
| PP&E, netmay include right-of-use assets (IFRS) | $1.23M | $897,627 |
| Total assets | $6.43M | $5.48M |
| Current liabilities | $673,207 | $168,849 |
| Total liabilities | $964,750 | $345,194 |
| Shareholders' equity | $5.70M | $5.37M |
| Shares outstanding | 4.34M | 2.57M |
| Cash flow statement | ||
| Operating cash flow | -$4.56M | -$6.25M |
| Capital expenditure | $603,890 | $952,497 |
| Free cash flow | -$5.17M | -$7.20M |
| Investing cash flow | -$603,890 | -$1.16M |
| Financing cash flow | $5.81M | $1.65M |
| Depreciation & amortization | $266,601 | $54,870 |
| Stock-based compensation | $365,309 | $1.01M |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.